About
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Current Value
$12.771 Year Return
Current Value
$12.771 Year Return
Key Details
Market Cap
$1.60B
P/E Ratio
73.67
1Y Stock Return
5.58%
1Y Revenue Growth
19.36%
Dividend Yield
0.00%
Price to Book
2.7
Strategies that include DVAX
Double maintains 3 strategies that include DVAX - Dynavax Technologies Corp.
Medium risk
$13,000
0.03%
Health Care Sector
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
348
High risk
$9,200
0.13%
US Small Cap
This strategy tracks a market-cap-weighted index of primarily small-cap US stocks, representing a small portion of the total market. This strategy focuses on the growth potential of smaller companies, offering investors targeted exposure to this dynamic segment of the US equity market. With a diversified portfolio of holdings it provides a broad approach to small-cap investing.
Top Sector
Financials
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
596
Stock's related to DVAX
The stocks that are correlated to DVAX - Dynavax Technologies Corp. are DNLI, ACLX, PRTA, ZD, ARCT
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 36.05% | $2.00B | -29.07% | 0.00% | |
A ACLXArcellx, Inc. | 35.81% | $3.69B | +6.38% | 0.00% |
P PRTAProthena Corp. Plc | 35.10% | $653.46M | -49.96% | 0.00% |
| 35.03% | $1.66B | -35.50% | 0.00% | |
| 34.88% | $276.62M | -68.85% | 0.00% | |
| 33.75% | $7.79B | +56.65% | 0.00% | |
V VCYTVeracyte, Inc. | 33.62% | $2.35B | +46.05% | 0.00% |
| 33.42% | $3.11B | -22.65% | 0.00% | |
| 32.67% | $1.07B | -19.62% | 0.00% | |
| 32.60% | $1.43B | -61.21% | 0.00% | |
| 31.99% | $1.85B | -37.74% | 0.00% | |
| 31.08% | $1.83B | -3.04% | 0.00% | |
F FTNTFortinet, Inc. | 31.06% | $75.42B | +37.52% | 0.00% |
| 30.79% | $8.88B | +57.41% | 1.30% | |
| 30.77% | $671.77M | -75.23% | 0.00% | |
| 30.73% | $677.40M | -80.55% | 0.00% | |
| 30.17% | $378.27M | -62.20% | 0.00% | |
A ALECAlector, Inc. | 30.15% | $116.92M | -79.97% | 0.00% |
E EXELExelixis, Inc. | 30.09% | $10.37B | +56.35% | 0.00% |
C CELCCelcuity, Inc. | 30.06% | $354.18M | -53.20% | 0.00% |
ETF's related to DVAX
The ETFs that are correlated to DVAX - Dynavax Technologies Corp. are PBE, XBI, IBB, CPRJ, GNOM
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 42.72% | $224.98M | 0.58% | |
X XBISPDR Biotech ETF | 41.99% | $4.76B | 0.35% |
| 39.39% | $5.61B | 0.45% | |
| 37.32% | $48.38M | 0.69% | |
| 35.97% | $47.13M | 0.5% | |
| 35.69% | $936.86M | 0.75% | |
| 35.10% | $358.88M | 0.35% | |
| 34.01% | $3.28B | 0.15% | |
| 33.83% | $797.08M | 0.6% | |
| 33.64% | $158.14M | 0.35% | |
| 33.42% | $1.08B | 0.56% | |
| 32.65% | $292.67M | 0% | |
| 30.72% | $100.03M | 0% | |
| 30.40% | $284.96M | 0.2% | |
| 30.35% | $144.85M | 0.79% | |
| 30.11% | $107.91M | 0.6% | |
| 29.69% | $10.92B | 0.07% | |
| 29.67% | $10.72B | 0.24% | |
| 29.64% | $62.65B | 0.19% | |
| 29.60% | $833.42M | 0.6% | |
News
Finnhub
Dynavax's Board is Overseeing Record Operational and Financial PerformanceOutlines Extensive Engagement with Deep Track and Multiple Attempts to Reach a ResolutionEMERYVILLE, Calif., April 3, 2025...
Yahoo
The resignation of one of the FDA's top officials, Peter Marks, is worrying Wall Street as they await a replacement.
Yahoo
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Yahoo
The consensus price target hints at an 83.1% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo
GREENWICH, Conn., March 10, 2025--Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.34% of the Company’s outstanding shares, today sent a letter to the Company’s Board of Directors (the "Board") related to Deep Track’s nomination of four highly qualified candidates for election to the Company’s Board of Directors (
Yahoo
Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, has entered into privately negotiated exchange and subscription agreements (the "Exchange Agreements") with a limited number of holders of its outstanding 2.50% Convertible Senior Notes due 2026 (the "2026 Notes") and one new investor, pursuant to which the Company will issue $225 million aggregate principal amount of 2.0% Convertible Senior Notes due
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds